To expand access to affordable, high-quality diagnostic tests across India
Redcliffe Lifetech has raised $61 million led by LeapFrog Investments (LeapFrog), with participation from Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners.
The investment will be used to expand Redcliffe’s geographic reach across India, with a focus on expanding its low-cost but high quality Direct to Consumer Diagnostics into Tier II, III and IV cities, providing affordable, rapid, and convenient pathology services from glucose to genetics in millions of households. Funding will be used to scale Redcliffe’s platform and increase its product offerings to radiology, disease data profiling and lifestyle management, furthering its mission to shift India’s healthcare focus from treatment to early diagnosis and prevention.
Dheeraj Jain, Founder of Redcliffe, said “The investment will help us scale rapidly to achieve our goal to reach 500M+ Indians within the next five years.”
